litlas
Log inCreate account

Socrates E. Papapoulos

Active 1979–2025

113
Papers
23,922
Citations
87
h-index
112
i10-index

Citations

Citations per year for Socrates E. Papapoulos1979: 1 citations1980: 5 citations1981: 6 citations1982: 5 citations1983: 6 citations1984: 8 citations1985: 6 citations1986: 3 citations1987: 8 citations1988: 2 citations1989: 5 citations1990: 4 citations1991: 13 citations1992: 17 citations1993: 21 citations1994: 22 citations1995: 38 citations1996: 55 citations1997: 61 citations1998: 57 citations1999: 59 citations2000: 92 citations2001: 107 citations2002: 137 citations2003: 162 citations2004: 152 citations2005: 149 citations2006: 181 citations2007: 179 citations2008: 226 citations2009: 184 citations2010: 231 citations2011: 250 citations2012: 239 citations2013: 214 citations2014: 221 citations2015: 163 citations2016: 201 citations2017: 168 citations2018: 174 citations2019: 518 citations2020: 551 citations2021: 429 citations2022: 346 citations2023: 230 citations2024: 354 citations2025: 186 citations2026: 7 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,988 citing papers, 26.5% of this breakdownUnited Kingdom: 671 citing papers, 8.9% of this breakdownChina: 519 citing papers, 6.9% of this breakdownItaly: 332 citing papers, 4.4% of this breakdownNetherlands: 319 citing papers, 4.3% of this breakdownCanada: 316 citing papers, 4.2% of this breakdownAustralia: 314 citing papers, 4.2% of this breakdownGermany: 305 citing papers, 4.1% of this breakdownJapan: 251 citing papers, 3.3% of this breakdownSwitzerland: 246 citing papers, 3.3% of this breakdownFrance: 241 citing papers, 3.2% of this breakdownBelgium: 176 citing papers, 2.3% of this breakdown
0%26.5%Other 24.4%

Institutions

Fields

  • Medicine65%
  • Biochemistry, Genetics and Molecular Biology26.3%
  • Engineering3.4%
  • Immunology and Microbiology1.3%
  • Dentistry0.9%
  • Neuroscience0.6%
  • Other2.5%

Topics

  • Bone health and treatments12.9%
  • Bone health and osteoporosis research12.1%
  • Bone Metabolism and Diseases9.7%
  • Bone and Joint Diseases3.8%
  • Parathyroid Disorders and Treatments2.6%
  • Hip and Femur Fractures1.8%
  • Other57.1%

Coauthors

All papers

Open in search
  1. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

    Authors: Henry G. Bone, Rachel B. Wagman, Maria Luisa Brandi, Jacques P. Brown, Roland Chapurlat, Steven R. Cummings, E. J. Czerwiński, Astrid Fahrleitner‐Pammer, David L. Kendler, Kurt Lippuner, Jean‐Yves Reginster, Christian Roux, Jorge Malouf, Michelle N. Bradley, Nadia Daizadeh, Andrea Wang, Paula Dakin, Nicola Pannacciulli, David W. Dempster, Socrates E. Papapoulos - The Lancet Diabetes & Endocrinology 2017 cited by 961

  2. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research

    Authors: Elizabeth Shane, David B. Burr, Bo Abrahamsen, Robert A. Adler, Thomas D. Brown, Angela M. Cheung, Felicia Cosman, Jeffrey R. Curtis, Richard Dell, David W. Dempster, Peter R. Ebeling, Thomas A. Einhorn, Harry K. Genant, Piet Geusens, Klaus Klaushofer, Joseph M. Lane, Fergus McKiernan, Ross E. McKinney, Alvin Choong Meng Ng, Jeri W. Nieves, Regis J. O’Keefe, Socrates E. Papapoulos, Tet Sen Howe, Marjolein C. H. van der Meulen, Robert S. Weinstein, Michael P. Whyte - Journal of Bone and Mineral Research 2013 cited by 2,118

  3. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

    Authors: Henry G. Bone, Felicia Cosman, Paul D. Miller, Gregory C. Williams, Gary Hattersley, Ming‐yi Hu, Lorraine A. Fitzpatrick, Bruce Mitlak, Socrates E. Papapoulos, René Rizzoli, Robin K. Dore, John P. Bilezikian, Kenneth G. Saag - The Journal of Clinical Endocrinology & Metabolism 2018 cited by 201

  4. Interim Report and Recommendations of the World Health Organization Task-Force for Osteoporosis

    Authors: Harry K. Genant, Cyrus Cooper, Gyula Poór, Ian Reid, George E. Ehrlich, J. A. Kanis, B. E. C. Nordin, Elizabeth Barrett‐Connor, Dennis M. Black, Jean‐Philippe Bonjour, Bess Dawson‐Hughes, P.D. Delmas, J. Dequeker, Sérgio Ragi Eis, C. Gennari, O Johnell, C. Conrad Johnston, E. M. C. Lau, Uri Liberman, Robert S. Lindsay, T. John Martin, Basel Masri, C. Mautalén, Pierre J. Meunier, Paul D. Miller, Ambrish Mithal, Hirotoshi Morii, Socrates E. Papapoulos, Anthony D. Woolf, Wei Yu, Nikolai Khaltaev - Osteoporosis International 1999 cited by 786

  5. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

    Authors: Michael R. McClung, Michelle L. O’Donoghue, Socrates E. Papapoulos, Henry G. Bone, Bente Langdahl, Kenneth G. Saag, Ian R. Reid, Douglas P. Kiel, Ilaria Cavallari, Marc P. Bonaca, Stephen D. Wiviott, Tobias De Villiers, Ling Xu, Kurt Lippuner, Toshitaka Nakamura, Jean‐Yves Reginster, Jose Adolfo Rodriguez-Portales, C. Roux, José Zanchetta, Cristiano A. F. Zerbini, Jeong‐Gun Park, KyungAh Im, Abby Cange, Laura T. Grip, Norman Heyden, Carolyn DaSilva, Dosinda Cohn, Rachid Massaad, Boyd B. Scott, Nadia Verbruggen, Deborah M. Gurner, Deborah L. Miller, Micki L Blair, Adam B. Polis, S. Aubrey Stoch, Arthur C. Santora, Antonio Lombardi, Albert Leung, Keith D. Kaufman, Marc S. Sabatine, C. Mautalén, Z. Man, José Zanchetta, C. Magaril, Philip N. Sambrook, Jean‐Yves Reginster, Piet Geusens, Stefan Goemaere, Ben Hur Albergaria, Cristiano A. F. Zerbini, Marise Lazaretti Castro, Luiz Henrique de Gregório, Румен Стоилов, Anna-Maria I Borissova, Kiril Hristov Hristozov, Nataliya Temelkova, Ivona Daskalova, Stefka I Kuzmanova, Daniela Yaneva-Bichovska, Anastas Batalov, Pablo Riedemann, José Adolfo Rodríguez Portales, Hai Tang, Han-min Zhu, Zhenlin Zhang, Aijun Chao, Yali Hu, Zhiming Liu, Ju-ming Lu, Ming-cai Qiu, Xin Gao, Shaofen Zhang, Ling Xu, Weibo Xia, Eryuan Liao, Wenying Yang, Wen Wu, Kerong Dai, Renming Hu, Hai Tang, Juan José Jaller, Francisco Cabal, José Fernando Molina, Carlos Curé, Hernan Yupanqui-Lozno, Philippe Chalem, John Londoño, Maurício Abello, Edgardo D Tobias, William Otero, Tatjana Nikolić, Blazenka Miskic, J Štěpán, Václav Vyskočil, Libor Novosád, Jan Slesinger, Pavel Novosad, Erika Vlckova, Ladislav Bortlík, Eva Dokoupilová and 313 more - The Lancet Diabetes & Endocrinology 2019 cited by 169

  6. The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study

    Authors: Eugène McCloskey, J. Rathi, S. Heijmans, Mark Blagden, Bernard Cortet, E. J. Czerwiński, Peyman Hadji, Juraj Payer, Kerry Palmer, Robert Stad, James O’Kelly, Socrates E. Papapoulos - Osteoporosis International 2020 cited by 158

  7. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

    Authors: Kenneth Poole, Rutger L. van Bezooijen, N. Loveridge, Herman A. Hamersma, Socrates E. Papapoulos, Clemens W.G.M. Löwik, J. Reeve - The FASEB Journal 2005 cited by 962

  8. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial

    Authors: Athanasios D. Anastasilakis, Socrates E. Papapoulos, Stergios A. Pοlyzos, Natasha M. Appelman‐Dijkstra, Polyzois Makras - Journal of Bone and Mineral Research 2019 cited by 153

  9. Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years

    Authors: Nelson B. Watts, John T. Grbic, Neil Binkley, Socrates E. Papapoulos, Peter Butler, Xiang Yin, Antoniette Tierney, Rachel B. Wagman, Michael R. McClung - The Journal of Clinical Endocrinology & Metabolism 2019 cited by 99

  10. Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist

    Authors: Rutger L. van Bezooijen, Bernard A.J. Roelen, Annemieke Visser, L. van der Wee-Pals, Edwin de Wilt, Marcel Karperien, Herman A. Hamersma, Socrates E. Papapoulos, Peter ten Dijke, Clemens W.G.M. Löwik - The Journal of Experimental Medicine 2004 cited by 883

  11. The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation

    Authors: Polyzois Makras, Natasha M. Appelman‐Dijkstra, Socrates E. Papapoulos, Sandra van Wissen, Elizabeth M. Winter, Stergios A. Pοlyzos, Maria P. Yavropoulou, Athanasios D. Anastasilakis - The Journal of Clinical Endocrinology & Metabolism 2021 cited by 60

  12. Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis

    Authors: Natasha M. Appelman‐Dijkstra, Socrates E. Papapoulos - Drugs 2015 cited by 115

  13. Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway

    Authors: Natasha M. Appelman‐Dijkstra, Socrates E. Papapoulos - Nature Reviews Endocrinology 2018 cited by 78

  14. Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

    Authors: Socrates E. Papapoulos, Roland Chapurlat, Cesar Libanati, Maria Luisa Brandi, Jacques P. Brown, E. J. Czerwiński, Marc-Antoine Krieg, Z. Man, Dan Mellström, S. Radominski, Jean‐Yves Reginster, Heinrich Resch, Jose Andrés Román Ivorra, Christian Roux, Eric Vittinghoff, Matthew Austin, Nadia Daizadeh, Michelle N. Bradley, Andreas Grauer, Steven R. Cummings, Henry G. Bone - Journal of Bone and Mineral Research 2011 cited by 344

  15. Expression of Vascular Endothelial Growth Factors and Their Receptors during Osteoblast Differentiation

    Authors: Martine Deckers, Marcel Karperien, Chris van der Bent, Takeyoshi Yamashita, Socrates E. Papapoulos, Clemens W.G.M. Löwik - Endocrinology 2000 cited by 533

  16. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

    Authors: Socrates E. Papapoulos, Kurt Lippuner, Christian Roux, Celia J. F. Lin, David L. Kendler, E. Michael Lewiecki, Maria Luisa Brandi, E. J. Czerwiński, Edward Franek, P. Lakatos, C. Mautalén, Salvatore Minisola, Jean‐Yves Reginster, S. Jensen, Nadia Daizadeh, A. Wang, Marc A. Gavin, Cesar Libanati, Rachel B. Wagman, Henry G. Bone - Osteoporosis International 2015 cited by 277

  17. Prolonged Bisphosphonate Release after Treatment in Children

    Authors: Socrates E. Papapoulos, Serge C.L.M. Cremers - New England Journal of Medicine 2007 cited by 211

  18. Bone Morphogenetic Proteins Stimulate Angiogenesis through Osteoblast-Derived Vascular Endothelial Growth Factor A

    Authors: Martine Deckers, Rutger L. van Bezooijen, Geertje van der Horst, Jakomijn Hoogendam, Chris van der Bent, Socrates E. Papapoulos, Clemens W.G.M. Löwik - Endocrinology 2002 cited by 617

  19. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation

    Authors: Rutger L. van Bezooijen, Peter ten Dijke, Socrates E. Papapoulos, Clemens W.G.M. Löwik - Cytokine & Growth Factor Reviews 2005 cited by 367

  20. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial

    Authors: John P. Bilezikian, Gary Hattersley, Bruce Mitlak, Ming‐yi Hu, Lorraine A. Fitzpatrick, Christine Dabrowski, Paul D. Miller, Socrates E. Papapoulos - Current Medical Research and Opinion 2019 cited by 46

  21. Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial

    Authors: Socrates E. Papapoulos, Henry G. Bone, Felicia Cosman, David W. Dempster, Michael R. McClung, Toshitaka Nakamura, José Fernando Molina Restrepo, Mary Bouxsein, Dosinda Cohn, Anne de Papp, Rachid Massaad, Arthur C. Santora - Journal of Bone and Mineral Research 2020 cited by 26

  22. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis

    Authors: René Rizzoli, Nansa Burlet, David L. Cahall, Pierre D. Delmas, Erik Fink Eriksen, Dieter Felsenberg, John T. Grbic, Mats Jontell, Regina Landesberg, Andrea Laslop, Martina Wollenhaupt, Socrates E. Papapoulos, Orhan Sezer, Michael Sprafka, Jean‐Yves Reginster - Bone 2008 cited by 221

  23. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment

    Authors: Athanasios D. Anastasilakis, Maria P. Yavropoulou, Polyzois Makras, G Sakellariou, Fotini Papadopoulou, Spyridon Gerou, Socrates E. Papapoulos - European Journal of Endocrinology 2017 cited by 86

  24. Denosumab in Patients With Fibrous Dysplasia Previously Treated With Bisphosphonates

    Authors: B.C.J. Majoor, Socrates E. Papapoulos, P. D. S. Dijkstra, Marta Fiocco, Neveen A. T. Hamdy, Natasha M. Appelman‐Dijkstra - The Journal of Clinical Endocrinology & Metabolism 2019 cited by 75